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ABSTRACT 
 
 
 
The prevention of mother-to-child transmission is one of the most powerful tools in 
human immunodeficiency virus type 1 (HIV-1) prevention and has huge potential to 
improve both maternal and child health.  In the absence of any preventative measures, 
infants born to and breastfed by their HIV-positive mothers have roughly a one-in-three 
chance of acquiring the infection themselves.  HIV can be passed on from mother-to-child 
during pregnancy, during labor and delivery, and even after during breastfeeding.   
Intrapartum and neonatal single-dose nevirapine (sd-NVP) is the foundation of 
preventing mother-to-child transmission in lower resource settings where it has been used 
alone or as part of combination regimens.  Both its simplicity and its long plasma half-life 
contribute to the success of sd-NVP based therapy.  However, sd-NVP frequently results in 
HIV-1 viral resistance in mothers and children who become HIV infected despite 
prophylaxis.  Sd-NVP leads to the development of non-nucleoside reverse transcriptase 
inhibitors (NNRTI) drug resistance, compromising the success of treatment of mother and 
child with subsequent antiretroviral combinations.  Resistance to NNRTIs is particularly 
worrisome in lower resource settings since many subsequent regimens for maternal and 
infant antiretroviral therapy include a NNRTI drug.   
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AN OVERVIEW OF HIV-AIDS 
HIV-1, the human immunodeficiency virus, is a retrovirus that can lead to acquired 
immune deficiency syndrome (AIDS).  As a retrovirus, HIV stores its genetic information on 
single-stranded RNA instead of double-stranded DNA.  After reverse transcription from the 
RNA template, HIV DNA enters the nuclei of the immune system’s helper T lymphocytes 
(CD4+ cells) and is integrated into the cell’s DNA.  After infection, HIV then uses CD4+ cells 
as hosts and instructs each cell to make copies of the original virus.  New virus particles are 
assembled and leave the cell to infect other CD4+ cells throughout the body.  This entire 
process of HIV replication depletes the number of CD4+ cells, causing the immune system to 
become suppressed over time (Stine 2010).  There is a less common, yet closely related 
strain of HIV called HIV-2 and unless otherwise stated, all subsequent mention of HIV is a 
reference to HIV-1.  
HIV is the greatest health crisis the world faces today.  An estimated 33 million 
people are living with HIV and an increasing number of women and children are being 
claimed by AIDS-related illnesses or death.  Mother-to-child transmission (MTCT) is the 
most prevalent source of HIV infection in children.  In 2000, the World Health Organization 
(WHO) issued recommendations on the use of antiretroviral drugs (ARVs) for preventing 
MTCT of HIV (WHO 2010).  This thesis will discuss drug resistance induced by single-dose 
nevirapine (sd-NVP), a short-course ARV regimen used to prevent MTCT, which has been 
shown to not fully suppress the virus.  
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MOTHER-TO-CHILD TRANSMISSION 
 
Figure 1.  MTCT is possible during pregnancy, labor and delivery, and throughout breast 
feeding at different proportions (Adapted from ICAP 2010).  
 
Of the 1,200 new pediatric infections occurring daily, more than 90% are estimated 
to be attributed to mother-to-child transmission (MTCT) (UNAIDS 2009).  MTCT occurs 
when an HIV-infected woman passes the virus to her baby.  As depicted in Figure 1, this can 
happen during pregnancy, labor and delivery, or while breastfeeding.   Not all infants born 
to women living with HIV will acquire HIV infection.  Without any preventative measures, 
approximately 25-45% of children will acquire HIV from their untreated mother.  The 
proportion of children who acquire infection varies by the timing of exposure.  There is a 
disproportionately high percentage of infections, 35-40%, occurring during labor and 
delivery compared with pregnancy (Abrams 2010).  During pregnancy, a woman can 
transmit the virus to her fetus in utero as the virus crosses over from the mother into the 
fetal bloodstream (Garcia et al. 1999 “Methods”).  Although, it is more likely for newborns 
to acquire HIV during delivery by ingesting blood or other infected maternal fluids (Kuhn et 
al. 1994).  If breastfed, the newborn may become infected from breast milk.  The likelihood 
of infection during breastfeeding depends on the duration of breastfeeding and if the baby 
is exclusively fed breast milk or if there is mixed feeding (Abrams 2010).  With cesarean 
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sections and the use of antiretroviral drugs, the risk of MTCT can be greatly reduced (WHO 
2010).  
 
ANTI-HIV THERAPY 
 Although there is no cure for HIV, there are drugs called antiretrovirals (ARVs) that 
suppress the reproduction of the virus dramatically and help maintain the immune system.  
At present there are six different classes of antiretroviral HIV-drugs available. 
1. Fusion inhibitors (FIs).  FIs are also known as entry inhibitors and work outside the cell 
to prevent the first stage of HIV replication.  They prevent HIV from entering the CD4+ 
cell by blocking fusion of HIV’s outer membrane with the CD4+ cell membrane (Levy 
2007).  
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs).  NNRTIs bind 
noncompetitively to reverse transcriptase, which HIV uses to replicate, and inhibit the 
enzyme.  This stops HIV from reproducing by preventing the conversion of RNA to DNA 
(Stine 2010).   
3. Nucleoside reverse transcriptase inhibitors (NRTIs).  NRTIs are sometimes referred to as 
“nukes” and like NNRTIs, interfere with the function of reverse transcriptase.  NRTIs act 
as false substrates for reverse transcriptase, causing chain termination.  This causes 
incomplete DNA synthesis and prevents HIV replication (Stine 2010). 
4. Integrase inhibitors (IIs).  IIs are a new drug class that blocks integrase, an enzyme that 
integrates HIV DNA into the nucleus of CD4+ cells (Stine 2010).  The first II, raltegravir, 
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was approved by the U.S. Food and Drug Administration (FDA) in 2007 and can be 
administered to patients with NNRTI resistance (Hammer et al. 2008). 
5. Protease inhibitors (PIs).  PIs work at the last stage of HIV’s replication cycle by targeting 
the HIV-1 protease enzyme which the virus uses to complete replication.  By binding to 
HIV-1 protease, PIs prevent mature, infectious HIV from being successfully assembled 
and released from the infected CD4+ cell (Levy 2007). 
6. CCR5 receptor antagonists. This is a new drug class that targets the CCR5 receptor, a 
CD4+ co-receptor which is involved in the HIV entry process.  HIV binds to CCR5 receptor 
antagonists, blocking HIV from binding to CCR5 receptors on the cell and blocking entry 
of HIV (Stine 2010).   
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SEVERITY AND SCOPE OF THE PEDIATRIC HIV EPIDEMIC 
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Figure 2. More than two million children estimated to be living with HIV globally 1990-2008 
(Adapted from UNAIDS 2009). 
 
Recent statistics provided by the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) reveal the problematic and global immensity of MTCT.  Of the estimated 33.4 
million people living with HIV in 2008 alone, 2.1 million were children under 15 years of age 
(Figure 2).  Even further, 430,000 of the 2.1 million children were newly infected with HIV in 
that year with the majority of them contracting the virus during the perinatal and 
breastfeeding period (UNAIDS 2009).  Although this is a significant reduction from the 
estimated 500,000 in 2001, HIV continues to weigh heavily on child mortality in low 
resource countries especially those in sub-Saharan Africa.  It is estimated that 85% of HIV 
positive (HIV+) children are living in sub-Saharan Africa where more than 90% of pediatric 
infections are attributed to MTCT (UNAIDS 2008).  In contrast, new HIV infections in 
children are becoming increasingly rare in higher resource settings.  In 2009, less than 1,000 
children were estimated to have become infected in all of North America and Western 
Europe (UNAIDS 2010). 
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DISPARITY BETWEEN PREVENTING MOTHER-TO-CHILD TRANSMISSION IN 
LOWER AND HIGHER RESOURCE SETTINGS  
 
Although the pediatric HIV epidemic still rages overseas, it has been close to two 
decades since antiretroviral prophylaxis was proven effective in reducing MTCT.  In 1994, 
the landmark study Pediatric AIDS Clinical Trials Group Protocol 076 (PACTG 076) 
demonstrated efficacy of the NRTI zidovudine (ZDV) to significantly reduce MTCT of HIV 
(Abrams 2010).   
 
 
Figure 3. Summary of the PACTG 076 study design and its results (Adapted from Connor et al. 1994). 
 
As shown in Figure 3, the PACTG 076 study placed 409 HIV+ pregnant women who 
were not previously exposed to ARVs in either a ZDV group or a placebo group.  The 
mothers of the ZDV group were given 100mg of ZDV orally five times a day during weeks 14 
to 34 antepartum.  During intrapartum they were intravenously administered 2mg/kg body 
weight ZDV every hour and 1mg/kg every hour during delivery.  Their infant(s) were given 
2mg/kg body weight ZDV orally every six hours for the first six weeks of life.  Results 
revealed an 8.3% rate of HIV-1 transmission in the ZDV group, a large drop in comparison to 
the 25.5% transmission rate of the placebo group.  ZDV therapy also induced a 67.5% 
409 HIV+ pregnant women naïve to ARVs 
Treatment arm:  
ZDV 500mg/day weeks 14-34 antepartum  
+ ZDV 2mg/kg/hr intrapartum + ZDV 
1mg/kg/hr during delivery 
 
Placebo arm:  
False drug. Same timelines 
Transmission rate:  
8.3% 
Transmission rate: 
25.5% 
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reduction in relative risk of HIV-1 transmission.  A regimen based on this ZDV model soon 
became standard practice for PMTCT in high resource countries such as the United States 
(Connor et al.  1994).  However, the complexity and expense of this approach, which entails 
both oral and intravenous dosing, made it impractical for use in most lower resource 
countries.  
Despite the proven effectiveness of perinatal ZDV therapy based on the PACTG 076 
study, there still remains a need for less complex and more cost effective regimens that 
could be used in both higher resource and lower resource settings.  Today, the estimated 
MTCT rate is 30% in low resource countries.  In stark contrast, MTCT rates are reported at 1-
2% in most high resource settings around the world (Katz et al. 2008).  MTCT has virtually 
been eliminated in high resource settings as a result of voluntary testing and counseling, 
widespread and routine access to ARV prophylaxis directed at suppressive therapy in 
pregnant women, safe delivery practices, and the ability and safe use of breast milk 
substitutes—all of which will be discussed further on (Townsend 2008). First, it must be 
understood why this disparity between low and high resource settings seems to plague 
global MTCT prevention strategies.  
 
GLOBAL PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: INADEQUATE 
PREVENTION EFFORTS 
 
It is clear that there has not been great success preventing pediatric infections in low 
resource, high HIV prevalence settings.  Since prevention programs were put in place over a 
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decade ago, there has only been an estimated 200,000 averted infections and in 2008, only 
70,000 pediatric infections were averted as seen in Figure 4 (UNAIDS 2009).   
 
Figure 4. Estimated number of new pediatric infections with and without ARV prophylaxis, global 
level, 1996-2008 (UNAIDS 2009). 
 
Turning to the key elements that guide the global strategy on PMTCT it is easy to see 
why this is such a difficult problem in lower resource settings.   
 
ELEMENTS OF SUCCESS: PREVENTING MOTHER-TO-CHILD TRANSMISSION 
 
According to the United Nations, the four main elements of prevention that must be 
met are as follows:  
1. Prevention of HIV in women of childbearing age.   
In 2008, more than one million women were newly infected with HIV with an 
especially high risk among those entering reproductive years (UNAIDS 2009).  Female 
youth are at a disproportionately high risk of acquiring HIV.  There is a 3-5 fold higher 
prevalence of HIV among young girls in comparison to boys in high prevalence countries.   
  
9 
This can be seen in sub-Saharan Africa where 75% of youth living with HIV are females 
(WHO 2009).   
For women living in high HIV-prevalent settings, the greatest risk of acquiring 
infection is through marriage or cohabitation.  In a study done in Zambia and Rwanda, 
an estimated 55.1-92.7% of heterosexual transmission occurs within a marital or 
cohabiting relationship (Dunkle 2008).  Most heterosexual HIV transmission for women 
takes places within marriage or cohabitation, a time in which most women start thinking 
about family.  Therefore, counseling and testing for couples should be promoted to 
prevent any possible MTCT.  
2. Prevention of unwanted pregnancies.   
Worldwide, the prevention of unwanted pregnancies has not been met with 
success.  There is an average of 80 million unintended pregnancies worldwide annually 
among women (Abrams 2010).  Given this, it is not surprising that there is a very high 
unmet need for family planning among HIV-infected women.  In lower resource 
countries, more than a quarter of women living with HIV report no desire for their 
current pregnancy or the wish to delay their next pregnancy by two years (UNAIDS 
2010).  In order to produce better outcomes for babies and their mothers and prevent 
new pediatric infections, there must be a strengthening of family planning services 
along with contraceptive use.   
3. Prevention of transmission from an HIV+ woman to her child.   
Most efforts for PMTCT depend on identifying HIV+ pregnant women and 
providing them with ARV prophylaxis treatment.  In 2010, the proportion of pregnant 
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women in low and middle-income countries who received an HIV test reached 26%, up 
from 7% in 2005 (ICAP 2010).  Although this shows progress, it is still a low figure.  The 
development of these programs has been overwhelmed by the rapid and successful 
expansion of ARV treatment opportunities in low resource settings.  However, one must 
note the disproportionately smaller number of pregnant women presently receiving 
antiretroviral therapy (ART) in comparison to the high number who are eligible for 
treatment.  Since PMTCT programs are typically tacked on to already limited 
infrastructure for maternal-child health services, there has been a systematic failure to 
identify, prioritize, and treat pregnant women eligible for therapeutic ART.  This is 
estimated to be about 20% of all pregnant women if using a CD4+ count of less than 
200cells/μL.  These women are at the highest risk for MTCT and for mortality (UNAIDS 
2010).   
In order to successfully achieve PMTCT, the infant must remain HIV negative 
(HIV-).  It has been shown that an elective cesarean section reduces MTCT about 50% 
independent of ARV therapy (Garcia et al. 1999 “Mode”).  This is difficult to achieve in 
settings with limited implementation of PMTCT programs.  A limited infrastructure 
cannot provide a large number of antenatal care visits, institutional deliveries, or 
complex medical interventions.  And even if there is a program in place, most programs 
still rely on short-course, monotherapy ART regimens that are of modest effectiveness 
and prone to antiretroviral resistance.  Although short-course regimens are a relatively 
straightforward method of prevention, they only provide acute, episodic care rather 
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than recognizing the chronic nature and duration of exposure that occurs during 
pregnancy and breastfeeding (Abrams 2010).   
As stated previously, the risk of MTCT extends throughout breastfeeding.  In 
settings where breastfeeding is essential for child survival, milk substitutes are generally 
not safe or feasible.  Therefore, there is still a focus on the unsuccessful infant feeding 
methods (Abrams 2010). 
4. Providing care and treatment for HIV-infected mothers and their family.   
For every mother living with HIV, a family is affected.  If the disease kills a mother, 
it has the ability to fuel despair among her children and family.  It has recently been 
found that keeping HIV+ adults in the family healthy reduces the risk of pediatric HIV 
and orphanhood.  In their work in Uganda, Mermin and colleagues treated HIV+ adults 
with ART and cotrimoxazole, a sulfa drug that eliminates bacteria associated with 
common infections.  They found an 81% reduction in death of uninfected children less 
than ten years old within the household as well as a startling 93% reduction in 
orphanhood (Mermin et al. 2008).  
 
MATERNAL HEALTH INFLUENCES CHILD HEALTH OUTCOMES 
Over the last decade, scientists have identified two factors that have the biggest 
impact on transmission: the degree of advancement of maternal infection and ARV 
medications (Abrams 2010).  It is clear that both these factors have become linked and this 
interconnectedness will be discussed in detail later.  
  
12 
Women with advanced HIV disease are at the greatest risk for their own disease 
progression and for transmission. In 1999, Garcia and colleagues identified the relationship 
between the risk of MTCT and the maternal viral load.  As seen in Table 1, women with 
higher levels of plasma HIV RNA were associated with increasing rates of MTCT 
transmission.  The risk was 0% among women with less than 1,000copies/mL.  The highest 
rate of transmission was among women whose plasma HIV RNA levels exceeded 
100,000copies/mL with 40.6% of non-breastfeeding babies acquiring HIV (Garcia et al. 1999 
“Maternal”).  Using the data found in the Garcia et al. study, statistically the mean maternal 
HIV-1 RNA viral load of transmission is 30,0000copies/mL and the mean viral load of non-
transmitters is 10,000copies/mL.  
Table 1. Relationship between the maternal plasma HIV RNA and MTCT rates (Garcia et al. 1999 
“Maternal”). 
 
 
 Children born HIV+ to women with advanced HIV disease are more likely to show 
high viral loads during the first months of life and are at a higher risk of developing AIDS or 
dying (Shearer 1997).  Even those born HIV- have a higher risk of death when born to 
mothers with advanced HIV.  In a study done in Zimbabwe, it was found that uninfected 
infants born to infected mothers have at least twice the mortality rate of infants born to 
uninfected mothers (Marinda 2007).   
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ANTIRETROVIRAL PROPHYLAXIS IN REDUCING MOTHER-TO-CHILD 
TRANSMISSION OF HIV 
 
Antiretroviral drugs (ARVs) reduce perinatal transmission by several mechanisms, 
including lowering maternal antepartum viral load and providing the infant with pre- and 
post-exposure prophylaxis.  A combination of antepartum, intrapartum, and infant ARV 
prophylaxis is recommended to prevent MTCT (“Panel on Treatment” 2011). 
Lowering maternal viral load. Antenatal ARVs lessen the maternal viral load, which is 
particularly important in women with high viral loads.  Even among women with HIV RNA 
plasma levels less than 1,000copies/mL, ARV drugs have been shown to reduce the risk of 
transmission (Ioannidis et al. 2001).  
Providing infant with prophylaxis. An infant can become pre-exposed to ARVs when 
ARV drugs cross the placental barrier and create systemic drug levels in the fetus.  This 
mechanism of protection is important during the infant’s passage through the birth canal, a 
time in which it is exposed to the virus in the mother’s genital tract.  Infant post-exposure 
prophylaxis can be achieved by administering ARVs soon after birth. This intervention 
provides protection from prior exposure to the mother’s HIV virus that may have occurred 
through labor or passage through the birth canal (Garcia et al. 1999 “The Mode”).  
The efficacy of antiretroviral drugs in preventing mother-to-child transmission of HIV 
is multifactorial and varies with the type of regimen used and the duration over which it is 
administered.  Combination regimens include different types of antiretroviral drugs and are 
more efficacious than monotherapies.  Monotherapies, discussed later in detail, are prone 
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to antiretroviral resistance in the virus and may limit future therapeutic options when 
needed (“Panel on Treatment” 2011).   
 
Figure 5.  Timeline of MTCT and different ARV interventions and their points of interaction (Adapted 
from ICAP 2010). 
 
Antiretroviral medications given at any point along the timeline seen in Figure 5, can 
significantly decrease the risk of MTCT.  In addition, ARVs given to the mother for their own 
health can result in maternal mortality, so ARVs should be given to the mother for her own 
survival.  The timeline for MTCT in Figure 5 shows the different ARV interventions and their 
point of interaction.  Single-dose nevirapine (sd-NVP), a NNRTI, is the most commonly used 
ARV prophylaxis.  A single-dose is given to the laboring woman and her newborn infant.   
Sd-NVP interrupts transmission during labor and delivery and early postpartum period.   If 
an additional short course of the NRTI azidothymidine (AZT, also known as zidovudine) is 
taken during late pregnancy through delivery along with sd-NVP, protection extends 
through late pregnancy.  If a pregnant woman is treated for her own health, a maternal 
combination therapy or maternal ARV prophylaxis has the ability to protect both her and 
presumably her baby throughout the breastfeeding period.  There has also been a shown 
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efficacy for protection during the postpartum period in breastfeeding infants who receive 
daily NVP (Figure 5, ICAP 2010).  
 
 
Figure 6. Summary of the CHER study design (Adapted from Violari et al. 1994). 
 
In the Children with HIV Early Antiretroviral Therapy (CHER) study, recent results 
definitively determined there is an advantage to starting children on treatment before to 
development of disease manifestations.  In this landmark study, 377 infants six to twelve 
weeks of age who were not immune suppressed or symptomatic were randomized to start 
immediate treatment or deferred to ART when they met clinical criteria with a primary 
outcome of time to disease progression or death (Figure 6).  It was concluded that an early 
HIV diagnosis and early ARV therapy during the first months of life reduced early infant 
mortality by 76% and HIV progression by 75% (Figure 7, Violari et al. 2008).  
 
Figure 7.  Early treatment reduces the risk of death (Violari et al. 2008).  
377 ARV-naïve infants 6-12 weeks of age 
 
Immediate ARV therapy  
(n = 125) 
Deferred ARV therapy 
(n = 252) 
Primary outcome:  
time to disease progression or death 
  
16 
ANTIRETROVIRAL REGIMENS IN LOWER RESOURCE SETTINGS  
 Although antiretroviral regimens have been proven effective in the PMTCT, their 
scale up has not been effective in lower resource settings.  Current statistics provided by 
United Nations Children’s Fund (UNICEF) reveal the low uptake of HIV testing and ART for 
PMTCT in lower and middle resource settings.  In their Fourth Stocktaking Report based on 
2008 data, an estimated 21% of pregnant women living in lower resource countries 
received an HIV test.  Yet, only 45% of those who tested positive received some form of ARV 
therapy or prophylaxis, and only 32% of exposed babies received some form of ARV 
prophylaxis (UNICEF 2009, Figure 8).  And if an ARV is received, it is most commonly a 
single-dose of nevirapine, which will now be discussed.   
 
Figure 8.  Low uptake of HIV testing and ARV prophylaxis in lower resource countries, 2004-2008 
(Adapted from UNICEF 2009). 
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NEVIRAPINE 
Nevirapine (NVP), also marketed under the trade name Viramune, is a NNRTI 
produced by the U.S. manufacturer Boehringer Ingelheim Pharmaceuticals Inc.  NVP was 
first approved by the U.S. Food and Drug Administration (FDA) in 1996 for use in 
combination therapy and in 1998 for pediatric use (Menéndez-Arias et al. 2011).  Approval 
for combination therapy was based on a 1996 study done by D’Aquila and colleagues that 
showed that adding NVP to two NRTIs, zidovudine and didanosine, was more effective in 
increasing CD4+ counts and decreasing HIV viral load than zidovudine and didanosine alone 
(D’Aquila et al. 1996).  NVP is currently the only NNRTI drug with pediatric drug formulation 
and neonatal dosing (“Panel on Treatment” 2011).  
Structure. The chemical name of nevirapine is 11-cyclopropyl-5,11-dihydro-4-
methyl-6H-dipyrido[3,2-b:2',3'-e][l,4]diazepin-6-1 and the molecular formula is C15H14N4O.  
Its chemical structure can be seen in Figure 9 (Campiani et al. 2002).  
 
Figure 9. Chemical structure of nevirapine (Adapted from Menéndez-Arias et al. 2011). 
 
Mode of action. As a NNRTI, nevirapine is a potent noncompetitive inhibitor of the 
reverse transcriptase enzyme, preventing HIV’s viral RNA from being transcribed into DNA.  
NVP does not bind at the enzyme’s active site like NRTIs, but allosterically at the 
hydrophobic NNRTI pocket, a site away from the active site (Patel and Benfield 1996).  NVP 
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selectively inhibits HIV-1, but not HIV Type 2 (HIV-2) since the NNRTI pocket on HIV-2’s 
reverse transcriptase enzyme has a different structure and has a higher than 8,000 fold 
selectivity for infected than uninfected cells (Ren et al. 2002).  
Dosage. Nevirapine comes in a tablet and a liquid oral suspension. It has been found 
that higher concentrations of NVP (2.5-10mg/L) work best and can completely suppress 
viral replication in cell cultures and protect uninfected cells (Patel and Benfield 1996).  
Use in combination therapy. Addition of nevirapine to existing ART therapy produces 
a more rapid and sustained immunological and virological response.  Nevirapine shows a 
higher synergistic inhibitory activity in combination with NRTIs.  Due to the same molecular 
target, NNRTIs and NRTIs complement each other in interfering with viral replication even 
though they have different mechanisms of actions (Campiani et al. 2002).  This was seen in 
the D’Aquila et al. study that NVP’s FDA approval was based on.  
So, if nevirapine works best in combination with NNRTIs, why do lower resource 
countries rely on a single-dose of NVP to prevent mother-to-child transmission? 
 
NEVIRAPINE: WHY SINGLE-DOSE? 
HIVNET 012 trial.  The simplest of all PMTCT drug regimens was tested in the HIV 
Network for Prevention Trials (HIVNET) 012 study, which took place in Uganda between 
1997 and 1999.  This randomized clinical trial evaluated a simple ARV drug regimen to 
prevent the transmission of HIV-1 from an infected mother to her child in a breastfeeding 
population.   
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Figure 10. Summary of the HIVNET 012 trial design and its results (Adapted from Guay et al. 1999). 
 
As seen in Figure 10, the experimental drug regimen consisted of a single oral dose 
of 200mg nevirapine (sd-NVP) given at the onset of labor to HIV-infected pregnant women 
along with a single-dose of nevirapine (2mg/kg) given to the baby within 72 hours of life.  
The comparison group was given a zidovudine (ZDV) regimen consisting of a maternal oral 
dose of 600mg along with 300mg every three hours of labor, in addition to a 4mg/kg ZDV 
dose twice daily for the baby’s first week of life.  ZDV was previously shown effective in 
Conner et al.’s 1994 study.  The HIVNET 012 study showed that the NVP regimen reduced 
MTCT risk by 47% at 14 to 16 weeks compared to the ZDV regimen.  At that age, the overall 
transmission rate observed was 13.1% for the NVP group versus 25.1% for the ZDV group.  
The transmission rate for the ZDV group was similar to those observed in the placebo 
groups of other randomized clinical trials conducted in breastfeeding populations (Guay et 
al.  1999).   
With its findings that a single-dose of NVP given to the mother at the onset of labor 
and to the baby after delivery can halve the rate of HIV transmission, the HIVNET 012 study 
jumpstarted the implementation of sd-NVP regimens in low resource settings with high HIV 
HIV+ pregnant women naïve to ARVs 
 
Single-dose nevirapine 
Mother: 200mg dose 
Infant: 2mg/kg within 72hrs 
Zidovudine 
Mother: 600mg dose + 300mg every 3 hrs 
of delivery 
Infant: 4mg/kg twice daily for 1 week 
Transmission rate:  
13.1% 
Transmission rate: 
25.1% 
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prevalence.  Coupled with rapid testing, women attending antenatal clinics could now be 
counseled, tested, and given a single pill that could save the life of their child.   
An open access program by Boehringer Ingelheim Pharmaceuticals Inc., the U.S. 
manufacturer of NVP, and their local partners quickly facilitated the rapid expansion of 
PMTCT programs using sd-NVP throughout the world (Abrams 2010).  
 
IS SINGLE-DOSE NEVIRAPINE IDEAL? 
Without a doubt, the HIVNET 012 study had and still has major implications for the 
control of HIV transmission in many developing countries and has led to critical decisions in 
the international health care community.  The ease of administration and low cost of sd-
NVP makes it ideal for monotherapy for prophylaxis of perinatal transmission, especially in 
settings where there are less resources and not enough antenatal care (Abrams 2010).   
A study done by Marseille and colleagues in 1999 proposed the universal 
administration of sd-NVP to all pregnant women at the time of labor and delivery and to 
their newborns in settings with high HIV prevalence, regardless of HIV status (Marseille et 
al.  1999).  This proposal was based on the cost effectiveness (about $2/dose) and simplicity 
of sd-NVP along with taking into account the technological difficulties of administering HIV 
testing in pregnant women in these countries, the lack of prenatal care, and the relative 
safety of sd-NVP for mothers and infants (Peters et al.  1999).   
This proposal, however, has led to opposition from those who question the risk of 
drug resistance caused by repeated exposure to nevirapine (during repeated pregnancies) 
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and who point out that $4 is close to the annual health care expenditure per capita in some 
African countries that are severely afflicted by HIV infection and AIDS. 
 
PREGNANCY AND ANTIRETROVIRAL DRUG RESISTANCE 
 The development of ARV drug resistance is one of the major factors leading to 
therapeutic failure in HIV-infected individuals.  In pregnant mothers, there are specific 
concerns that differ from the nonpregnant population.  A pre-existing drug resistance to a 
drug used in an ARV regimen can diminish the regimen’s efficacy for PMTCT.  If a mother 
develops resistance to drugs used during pregnancy to stop MTCT, her future options may 
be limited.  In addition, infant treatment options may also become limited if the mother 
develops a resistant virus that is then transmitted to her fetus (“Panel on Treatment” 2011).   
Several factors unique to pregnancy may increase the risk of developing resistance.  
If drugs with significantly different half-lifes such as the combination of NVP and two NRTIs 
are included in the regimen and the mother discontinues ARV therapy after delivery, there 
is an increased chance of NNRTI resistance due to the persistent subtherapeutric drug 
levels.  Nausea and vomiting associated with early pregnancy may also compromise 
adherence and increase the risk of resistance (Lockman et al.  2007).   
 
ANTIRETROVIRAL RESISTANCE FOLLOWING SHORT-COURSE PROPHYLAXIS  
 Viral resistance may emerge during ARV treatment and occurs frequently with 
single-drug regimens and even more frequently with single-dose regimens.  Viral resistance 
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is a potential problem for women after short-term exposure to ARV drugs to prevent MTCT 
and for infants who become infected despite ARV prophylaxis.  
 Even before ARV drugs are administered, HIV that contains mutations associated 
with viral drug resistance is present at low levels not detectable using standard resistance 
assays.  Pre-existing resistant viral populations may be selected for or new mutations may 
develop with any ARV drug or drug regimen that does not fully suppress viral replication.  
Most studies have also reported that a high maternal plasma viral load or a low CD4+ count 
are associated with an increased risk of resistance to any ARV drug.  NNRTIs such as NVP are 
drugs for which a single mutation leads to high-level resistance, whereas most NRTI drugs 
require multiple sequential mutations to confer resistance (Mofenson et al. 2002).  
 
OVERVIEW OF ANTIRETROVIRAL RESISTANCE EMERGING FROM SINGLE-DOSE 
NEVIRAPINE 
 
Development of resistance associated with short-term use of ARV drugs for PMTCT 
is most common with sd-NVP.  Over the last decade there has been a great deal of work 
looking at the implications of NVP resistance mutations in mothers children who fail sd-NVP 
PMTCT prophylaxis.  Arrivé and colleagues published a meta-analysis of summarized data 
looking at prevalence of NVP resistance mutations in the plasma of the mothers and infants 
at four to eight weeks postpartum after sd-NVP use for PMTCT.  The pooled estimates of 
NVP resistance prevalence were found to be 35.7% in the mothers and 52.6% in the 
children following sd-NVP (Figure 8).  However, the administration of postpartum ARVs to 
the mother can significantly reduce the frequency of detection of NVP-resistant strains.  As 
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seen in Figure 11, the prevalence of NVP resistance can be significantly reduced to 4.5% in 
the mother and 16.5% in the child by adding short-course postpartum ARV therapy to 
standard sd-NVP (Arrivé et al.  2007). It is important to remember that NVP resistance is 
also associated with resistance to other NNRTIs due to the location of mutations on the 
reverse transcriptase gene.  
 
Figure 11. Plot of multiple studies grouped according to whether mothers and children received only 
sd-NVP or sd-NVP + additional ARVs at 4-8 weeks postpartum (Arrivé et al.  2007).  
 
Resistance to NVP develops rapidly if viral replication is not completely suppressed.  
Because of NVP’s long half-life, the drug can be detected in plasma up to three weeks after 
administration of a single-dose during labor and delivery (Cressey et al. 2005).  This long 
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half-life creates a long period of persistent subtherapeutic drug levels that cause a 
predisposition to the development of resistant strains of HIV (Arrivé et al.  2007).  Viral 
strains resistant to NVP were detected at six weeks postpartum in 19% of ARV-naïve women 
of the HIVNET 012 trial and in 15% of women on additional ARV therapy who received sd-
NVP during labor (Cunningham et al. 2002, Eshleman et al. 2001).  The use of sd-NVP is 
likely to result in HIV viral resistance which could lead to resistance of subsequent ARV 
treatment combinations.  
 
COMMON MUTATIONS FOLLOWING NEVIRAPINE TREATMENT 
 
Figure 12. Nevirapine associated mutations on the reverse transcriptase gene (Adapted from 
International AIDS Society-USA 2006). 
 
With nevirapine’s low genetic barrier for resistance, single-nucleotide changes in the 
viral genome can cause high-level resistance to NNRTIs.  The most prominent mutations 
found after exposure to NVP treatment are the Y181C mutation and the K103N mutation, 
correlating with amino acid changes in the hydrophobic pocket where NVP usually binds 
(Figure 12).  As stated previously, NNRTIs exert their antiviral effect against HIV by binding 
to reverse transcriptase in a hydrophobic pocket located next to the active site of the 
enzyme that blocks the process of DNA polymerzation, causing a conformational change in 
this enzyme (Patel and Benfield 1996).  The region of the hydrophobic pocket that NNRTIs 
100  103  106  108 181        188  190
L       K        V       V                    Y               Y G 
I        N      A      I                   C               C       A 
I        N M      I  I                L       A 
H
Amino acid, wild-type
Amino acid, substitution
conferring resistance
Amino acid position
Amino acid abbreviations: A, alanine; C, cysteine; G, glycine; H, histidine; I, isoleucine;  
K, lysine; L, leucine; M, methionine; N, asparagine; V, valine; Y, tyrosine  
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bind predominantly involves amino acid codons 98-108 and 179-190.  Since all NNRTIs bind 
within the same pocket, a mutation observed with one NNRTI is usually observed with all 
NNRTIs.  Therefore, viral strains which are NVP resistant are also usually resistant to other 
NNRTIs (Conway et al. 2001, Deeks 2006).  Resistance to NNRTIs occurs as a result of 
mutations that inhibit effective binding of the NNRTI, allowing DNA polymerization to 
proceed in an unrestricted manner (Deeks 2006).  
Furthermore, the predominant NVP resistance mutations appear at different time 
points.  In mothers, the Y181C mutation is predominant one week postpartum and the 
K103N is predominant six to eight weeks postpartum.  However, most infants with NVP 
resistance were noted to be infected at birth, suggesting that the resistance mutations were 
not being passed on from the mother, but instead when their actively replicating virus was 
exposed to NVP (WHO 2010).  Therefore, the transmission of resistant viral strains to infants 
is not associated with an increased risk of MTCT. 
 
SAFETY AND EFFICACY OF NEVIRAPINE PROPHYLAXIS FOR REDUCING HIV 
DURING BREASTFEEDING 
 
HIV transmission during breastfeeding has also reduced the overall effectiveness of 
efforts to prevent MTCT.  Multiple studies have found multiclass drug resistance in 
breastfeeding infants who became infected despite NVP prophylaxis.  The overall risk of HIV 
transmission through breastfeeding is around 35-40% during the first two years of life, with 
the greatest risk by the first six to fourteen weeks of life, a time in which about 60-70% of 
breast milk transmission occurs (ICAP 2010).  Despite this risk, WHO recommends that HIV-
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infected mothers living in lower resource countries exclusively breastfeed for at least six 
months to improve infant survival (WHO 2010).  
Resistance mutations have been found in maternal plasma and breast milk after sd-
NVP exposure.  In a study of twenty women from Zimbabwe, Lee and colleagues looked at 
paired specimens of plasma and breast milk.  They found that 50% of the plasma samples 
and 67% of the breast milk samples had detectable NNRTI mutations, predominantly the 
K103N mutation (Lee et al. 2005).  This observation of drug-resistance in sd-NVP exposed 
women who breastfeed created much concern and led to trials investigating the use of daily 
NVP to preserve safe breastfeeding among HIV infected women.    
To allow for breastfeeding, yet reduce transmission, NVP dosages were extended for 
up to six weeks of age in the “Six Week Extended-dose NVP” (SWEN) trial.  The SWEN trial 
compared postnatal infection in breastfeeding infants in Uganda, Ethiopia, and India who 
received sd-NVP or six weeks of daily NVP.  In infants uninfected at birth, MTCT at six weeks 
was 5.3% in the sd-NVP arm versus 2.5% in the extended NVP arm.  At six months, MTCT 
was 9.0% in the sd-NVP arm versus 6.9% in the extended NVP arm (Moorthy et al. 2009).  
Extended NVP allows for daily NVP prophylaxis for infants breastfeeding and lowers the rate 
of HIV infection in comparison to sd-NVP.   
Although the use of the SWEN regimen looks promising at preventing breast milk 
HIV transmission, a study completed by Moorthy and colleagues on the Indian arm of the 
SWEN trial showed that the SWEN regimen carries a high likelihood of NVP resistance if the 
infant becomes infected within the first six weeks of life.  As demonstrated in Figure 13, of 
the infants diagnosed with HIV by six weeks of age, the SWEN-exposed infants had a 
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significantly higher prevalence of NVP resistance at 92% than those who received sd-NVP, of 
which only 38% developed NVP resistance when detected by standard population 
sequencing.  After six weeks of age, the prevalence of NVP resistance did not differ among 
SWEN or sd-NVP exposed infants who became infected during breastfeeding (Figure 13, 
Moorthy et al.  2009).   As with sd-NVP, the value of preventing HIV infection in a large 
number of infants should be considered alongside the high risk of resistance associated with 
extended NVP prophylaxis. 
 
Figure 13. SWEN and sd-NVP exposed HIV+ infants diagnosed within the first six weeks of life or 
after (Adapted from Moorthy et al. 2009).  
 
 Similar findings to Moorthy et al. were found by Church and colleagues when they 
evaluated NVP resistance in the Ugandan SWEN cohort.  At six weeks, 84% of the 
breastfeeding infants had NVP resistance in comparison to 50% who were only given sd-
NVP (Figure 14A).  This is a 1.7 fold greater risk of resistance in SWEN group compared with 
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sd-NVP when tested at 6 weeks of age.  When a small group of these children were retested 
a six months, 100% of 7 children in the SWEN group continued to have detectable NVP 
resistance whereas only 1 of the 6 children, or 17%, in the sd-NVP group had detectable 
resistance (Figure 14B, Church et al. 2008).  These findings suggest that resistance is greater 
in children with longer duration of exposure.  
  
Figure 14. Nevirapine resistance results from SWEN and sd-NVP exposed infants. A, percentage of 
infants with NVP resistance within first six weeks of life. B, percentage of infants who had 
NVP resistance mutations at six weeks that were retested at six months (Adapted from 
Church et al. 2008).  
 
Resistance in breastfeeding HIV-infected infants of mothers on ART has also been 
demonstrated by the Kisumu breastfeeding study (KiBS) completed in Kenya.  In the KiBS, 
pregnant women received either NVP or the protease inhibitor nelfinavir (NFV) along with 
the nucleoside reverse transcriptase inhibitor combivir (AZT+3CT) from 34 weeks gestation 
through 6 months postpartum.  As seen in Figure 15, by six months of age, 24 infants were 
HIV infected.  Of the 24 infants, 9 were born to mothers on the NFV regimen and 15 were 
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born to mothers on the NVP regimen.  Resistance was detected among 9/9 (100%) of the 
NFV exposed infants and in 7/15 (47%) of the NVP exposed infants (Zeh et al. 2011)  
 
 
Figure 15. Summary of the KiBS study design and its results (Adapted from Zeh et al. 2011). 
 
 Mirochnick and colleagues decided to evaluate the serum concentrations of NVP 
and 3TC of the uninfected infants of mothers on antiretroviral therapy in the KiBS.  The 
median concentrations in breastmilk of NVP and 3TC were 1,214ng/mL and 4,546ng/mL in 
comparison to zidovudine’s 14ng/mL (Mirochnick et al.  2009).  These biologically significant 
concentrations of both NVP and 3TC in the infants demonstrate that NVP and 3TC can be 
transferred in breast milk. 
 
NEVIRAPINE-ASSOCIATED RESISTANCE MUTATIONS: IMPACT ON TREATMENT 
It is now well established that sd-NVP use and NVP use in general for PMTCT can 
cause viral mutations associated with NNRTI resistance.  Infants who fail prophylaxis and 
acquire infection despite NVP exposure tend to develop resistance.  So what does this all 
mean for the child with HIV infection presenting for treatment?  The small numbers of 
522 HIV+ pregnant women naïve to ARVs 
 
310 mothers on NVP+AZT+3TC 
 
212 mothers on NFV+AZT+3TC 
HIV+ infants at 6 months: 4.8% 
n = 15 
HIV+ infants at 6 months: 4.2% 
n = 9 
7 of 15 infants (47%) developed drug 
resistance to  maternal regimen 
All 9 infants (100%) developed drug 
resistance to maternal regimen 
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children infected in previous perinatal studies make it hard to determine especially when 
most have been studied only six to eight weeks after exposure.   
In the Nevirapine Resistance Study (NEVEREST), sd-NVP exposed children who were 
eligible for ART were started on a combination of LPV/r+AZT+3TC therapy.  Yet prior to 
initiation of treatment, resistance testing was done for 257 symptomatic children between 
the ages of six months and two years. Overall, 27% of the children had detectable NNRTI 
major mutations using standard population sequencing.  The Y181C mutation was found in 
21% of the children and the K103N mutation was found in 5% of the children.  Using allele 
specific PCR testing for low level frequencies, an additional 13% of Y181C mutations and 9% 
K103N mutations were detected.  As seen in Figure 16, young children are at a much higher 
risk for any NNRTI mutation in comparison to older children (Hunt et al. 2009).  This 
suggesting a fading of resistance over time, which may allows for ARV treatment 
subsequent to sd-NVP exposure.  
 
Figure 16. NNRTI resistance mutations at ART initiation in HIV+ children with prior exposure to sd-
NVP (Adapted from Hunt et al. 2009). 
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HIV DRUG RESISTANCE AT ANTIRETROVIRAL TREATMENT INITIATION 
SUBSEQUENT TO SINGLE-DOSE NEVIRAPINE EXPOSURE 
 
The first published study looking at treatment failure in children previously exposed 
to sd-NVP was presented by Lockman and colleagues in 2007.  They studied the response to 
NVP-based ARV treatment among thirty mothers and children who were previously part of 
a trial that involved the administration of either a placebo or sd-NVP for the prevention of 
MTCT.  The results were quite dismal.  As seen in Figure 17, there were significantly higher 
rates of virologic failure among both the mothers and children who previously received sd-
NVP in comparison to those previously in the placebo group after NVP-based ARV initiation.  
By 24 weeks, 77% of the children with previous sd-NVP exposure met viral failure with more 
than 400copies/mL (Lockman et al.  2007) 
 
Figure 17. Time to virologic failure in infants previously exposed to sd-NVP (Lockman et al. 2007).  
 
Subsequent ARV treatment after sd-NVP exposure was also studied in the 
International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) P1060 trial that 
was recently been completed by Palumbo and colleagues. This study was designed to 
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compare NVP versus LPV/r containing regimens given to ART-naïve children six months to 
three years of age who had prior exposure to sd-NVP.   
 
Figure 18. Summary of the P1060 study design (Adapted from Palumbo et al. 2010). 
 
As seen in Figure 18, the children were randomized to NVP+AZT/3TC or to 
LPV/r+AZT/3TC arms and the primary end point was virologic failure or discontinuation of 
treatment by week 24.  The Data and Safety Monitoring Board (DSMB) recommended 
closure of this study early due to its early findings.  More children in the NVP arm (39.6%) 
reached a primary viral end point in comparison to the LPV/r arm (21.7%) by 24 weeks.  This 
difference was most distinct in children under the age of one who were put on therapy, 
with 45.3% in the NVP arm meeting failure compared to 23.3% in the LPV/r arm (Figure 19).   
Baseline resistance to NVP was also detected at the initiation of treatment in 12% of the 
children studied and was predictive of treatment failure.  For the children in the NVP with 
detectable resistance prior to therapy, 83% failed in comparison to only 18% in the LVP/r 
arm with existing resistance (Palumbo et al.  2010). Since NVP is used widely for the 
prevention of MTCT in lower resource settings, alternative strategies are urgently needed.  
288 ARV-naïve infants 6 months to 3 years of age 
with prior sd-NVP exposure 
 
NVP+AZT/3TC 
 
 
LPV/r+AZT/3TC 
 
Primary outcome:  
time to disease progression or death 
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Figure 19.  Time to primary end point of virologic failure or discontinuation of treatment greater in 
NVP in comparison to LVP/r arm in children under 12 months of age (Palumbo et al. 
2010).  
 
Palumbo et al.’s trial along with the NEVEREST study both showed that there is no 
association between NNRTI mutations and protease inhibitor therapy (Palumbo et al. 2010, 
Hunt et al. 2011).  New WHO pediatric treatment guidelines now recommend the use of a 
boosted protease inhibitor such as LPV for therapy in all NVP-exposed children under two 
years of age (WHO 2010).  
 
2010 WORLD HEALTH GUIDELINES FOR THE PREVENTION OF MOTHER-TO-
CHILD TRANSMISSION 
 
The new 2010 WHO guidelines for PMTCT are based on two key approaches: lifelong 
ART and ARV prophylaxis.  Lifelong ART is for HIV+ women in need of treatment for their 
own health, which is also effective in reducing MTCT.  ARV prophylaxis prevents MTCT 
during pregnancy, labor and delivery, and breastfeeding for HIV+ women not in need of 
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treatment for their own health.  These revised guidelines are the first to include 
recommendations on ARV prophylaxis during breastfeeding where breastfeeding is the 
most appropriate choice (WHO 2010).  This allows PMTCT interventions to continue into the 
postpartum period. 
Figures 20 and 21, summarize the new guidelines for both HIV+ pregnant women 
and their infants.  As shown in Figure 20, there is now a focus on maternal therapeutic ARV 
for women with CD4+ counts less than 350cells/μL.  For healthier women with CD4+ counts 
greater than 350cells/μL, there are two comprehensive options for prophylaxis: A) AZT+ sd-
NVP during pregnancy and daily infant NVP during the post natal period or B) maternal ARV 
prophylaxis during pregnancy and infancy (WHO 2010).   
CD4 count > 350 cells/µL
Mother takes ARVs for her infant’s health
Option A (Maternal AZT)
 AZT from 14th week
 Sd-NVP in labor*
 AZT + 3TC in labor and delivery + 1 week 
post-partum*
* Can be omitted if mother receives > 4 
weeks of AZT during pregnancy  
Option B (Maternal triple ARV 
prophylaxis)
 triple ARVs from 14th week of 
pregnancy until 1 week after 
breastfeeding has finished  
CD4 count < 350 cells/µL
Mother takes ARVS for her own health
 Recommended course of triple ARVs to 
be started ASAP and taken indefinitely
Mother: HIV+ during pregnancy will receive ARVs
 
Figure 20. Summary of 2010 PMTCT WHO guidelines for HIV+ mothers in lower-resource countries 
(Adapted from WHO 2010). 
 
Figure 21 illustrates the new guidelines for infants born to HIV+ mothers.  All infants 
should now receive a course of medication which is linked to the drug regimen their mother 
is taking.  If the mother is taking ARVs for her own health, the infant should receive daily 
NVP for six weeks.  If the mother is only taking ARVs for her infant, then the infant should 
receive daily NVP until one week after breastfeeding is ended.  It is recommended that the 
child breastfeed for the first six months if there is no other safe option.  Afterwards, the 
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mother can supplement breast milk or complementary feed.  If the infant is not breastfed, 
they should receive daily NVP or AZT for six weeks (WHO 2010).  
Breastfeeding
Exclusively breastfeed for 6 months then complementary feed and continue 
breastfeeding for the first 12 months of life. Gradually wean.
Option A (Maternal AZT)
 If the mother is taking AZT for the infant, 
then the infant should have daily NVP 
until 1 week after breastfeeding has 
finished.
Option B (Maternal triple ARV 
prophylaxis)
• If the mother is taking ARVs for 
her health, then the infant should 
have daily AZT or NVP for 6 weeks 
Not breastfeeding 
(alternative feeding)
 Infant should have daily NVP or AZT for 
6 weeks
Infant: status is unknown or negative. Receives daily NVP or AZT
 
Figure 21. Summary of 2010 PMTCT WHO guidelines for infants born to HIV+ mothers in lower-
resource countries (Adapted from WHO 2010). 
 
With their recommendation of combination therapy instead of sd-NVP, the new 
PMTCT WHO guidelines have the potential of bringing transmission rates in lower resource 
settings to rival the one to two percent transmission rates in higher resource settings. In 
2010, Kuhn and colleagues reviewed the potential impact of the new WHO criteria for 
PMTCT using data from 1,025 HIV-inftected women and infants from Zambia.  The new 
criteria of using a CD4+ count below 350cells/μL required initiating therapy in 68% of 
pregnant women and if fully effective has the possibility of preventing 92% of maternal 
deaths and 88% of infant infections caused by MTCT (Kuhn et al. 2010).  
The problem of pediatric HIV seems so simple to solve.  Children need to be 
identified early on and started on appropriate treatment as seen in the new WHO 
guidelines.  Yet, what about all the children previously exposed to sd-NVP? 
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LOPINAVAR/RITONAVIR: ANOTHER OPTION FOR CHILDREN PREVIOUSLY 
EXPOSED TO NEVIRAPINE? 
 
 A number of other strategies have looked at whether or not there are other options 
for children who have been previously exposed to NVP and if there is other options besides 
NVP for life-long treatment in children.  However, as seen in Table 2, there are very few ARV 
medications currently approved for children in low resource settings (Adams 2010).  
Table 2. ARV medications approved and available for children in lower resource settings (Adapted 
from Abrams 2010).  
NNRTI NRTI 
Integrase 
Inhibitor 
Protease 
Inhibitor 
CCR5 receptor 
antagonist 
Fixed dose 
Combination 
NVP ABC 2 ------------ LPV/r 2 ------------- NVP+3TC+D4T 
EFV 1 DDI     
 D4T     
 3TC     
 ZDV     
1 Only for children >3 years 
2 Not widely available in a majority lower resource countries 
3 Limited availability in some lower resource countries 
 
The global ART scale-up has been anchored on the usage of NNRTI-based regimens 
due to their low cost including generic and pediatric formulations.  Protease inhibitor-based 
ART is reserved for second-line therapy and has a limited availability and relatively high 
cost.  Lopinavar/ritonavir (LPV/r) is currently the only protease inhibitor option available for 
young children since dosing and/or formulations of other PIs are not available or approved.   
LPV/r was recently used in another arm of the NEVEREST study that looked at sd-
NVP exposed children with NNRTI resistance.  Their findings indicate that an induction 
period with full viral suppression after the administration of LPV/r+3TC+d4T (d4T: 
stavudine) allows for the safe reintroduction of NNRTIs and the ability to stop LPV/r use and 
reuse it as a second line therapy.   
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Figure 22. Summary of the NEVEREST NVP resistance study design (Adapted from Cooavadia et al. 
2009). 
  
As shown in the diagram of the study in Figure 22, 323 sd-NVP exposed infants 
started LPV/r+3TC+d4T treatment and 195 reached viral suppression.  The 195 were then 
randomized to LPV/r or switched to NVP.  The primary endpoint was a sustained viral 
suppression of less than 50copies/mL or 52 weeks.  The children who switched to NVP were 
more likely to fully suppress to less than 50copies/mL.  However, upon looking at Figure 23 
and the more clinically meaningfully sustained viral suppression of less than 1,000copies/mL 
at 52 weeks, fewer children in the NVP switch group (84.9%) than in the control group 
(96.8%) were able to maintain suppression (Coovadia et al. 2009).  This study illustrates that 
sd-NVP associated NNRTI mutations prior to the initiation of therapy are directly related to 
the risk of losing suppression when the infant is switched back to NVP.  
Stay on LPV/r: 
96 infants 
 
195 infants eligible for randomization 
 
323 sd-NVP exposed children  
6 weeks to 24 months of age 
Stay on LPV/r: 
99 infants 
Primary outcome:  
52 weeks or viral suppression (<50copies/mL) 
 
Start LPV/r+3TC+d4T 
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Figure 23. NEVEREST NVP resistance study: sustained viral suppression on children in the NVP switch 
group in comparison to the control group at 52 weeks.  
 
 Although LPV/r seems is definitely an option for PMTCT, there are still many issues 
that come along with it.  Currently, only a liquid form of LPV/r is available for infants and is 
poorly palatable.  LPV/r also requires a cold chain, which is not ideal in transporting the ARV 
to distant clinics in hot climates served by poorly developed transport networks (Barragan 
et al. 2008).  In addition, LPV/r cannot be used in many HIV+ children who are co-infected 
with tuberculosis due to its interactions with rifampin, a widely used tuberculosis treatment 
medication, which jeopardizes viral suppression (Abrams 2010).  
 So as recent studies support the replacement of sd-NVP with LPV/r, it is important to 
note that the ARV rollout in most low resource countries has been saving children, 
especially young children.  
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POSITIVE EFFECTS OF ANTIRETROVIRAL THERAPY PROGRAMS IN LOW 
RESOURCE SETTINGS 
 
Although it seems like at times PMTCT strategies are failing, there are generally 
favorable results of ART for children in low resource settings.  Even with a modestly 
functioning PMTCT program, benefits for survival of young children are becoming quickly 
evident.  With more comprehensive treatment coverage, and more efficient PMTCT 
including AZT in addition to sd-NVP, further significant reductions in early life mortality have 
been achieved.   
 
Figure 24. Children receiving ART have high weight-for-age Z scores and CD4+ percentages, Zambia 
(Bolton-Moore et al. 2007). 
 
A study done in Zambia demonstrates the excellence of PMTCT programs based on 
simple regimens in children, especially in young children.  In the study, care was provided by 
clinicians such as nurses and clinical officers in primary health care settings.  Children 
received three-drug ART (AZT+3TC+NVP) if they tested positive for HIV antibodies and 
showed signs of immunosuppression.  In the study, surviving children less than 18 months 
had high weight-for-age Z scores and high CD4+ counts (Figure 24, Bolton-Moore et al, 
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2007).  Improvement in weight was more pronounced in the younger children as compared 
with the older children and the average child experienced more than a doubling of his or 
her CD4+ cell percentage in the first year of ART.  These both show that good clinical 
outcomes can be obtained by treating children with ART at primary health care facilities 
using nonphysician clinicians in lower resource settings such as sub-Saharan Africa.  
 
Figure 25. Decline in early life mortality with PMTCT ART services in KwaZulu-Natal, South Africa 
(Adapted from Ndirangua et al. 2010).  
 
When regimens based on AZT plus sd-NVP for the mother and child are not 
acceptable or feasible, ARV prophylaxis using solely sd-NVP remains a practical regimen.  
Progress in implementing programs to prevent MTCT based on single-dose maternal and 
infant NVP or other short course regimens should not be undermined.  There has been a 
large decline in early life mortality of children born to HIV+ mothers in KwaZulu-Natal, South 
Africa from 2001 to 2006 with the implementation of PMTCT and ART programs based on 
sd-NVP (Figure 25).  Although crude mortality rates in the neonatal and early childhood ages 
Under 2 
Post-neonatal 
1-2 yrs old 
Neonatal 
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remained relatively stable, there was a large decline in the postneonatal mortality rates and 
the numbers of deaths in children under two years of age declined by 49% from 2000 to 
2006. With the rollout of a PMTCT program in 2001, child mortality rates declined by 36% 
folllowed by a futher 20% decline after an HIV treatment program based on sd-NVP was 
established in 2004 (Ndirangua et al. 2010).  These findings confirm that even with a 
modestly functioning PMTCT and HIV treatment program, children are benefiting.  
 
Figure 26. Increased use of more complex ARV regimens in ICAP-supported PMTCT programs 2007-
2009 in eight different African countries (ICAP 2010).  
 
The International Center for AIDS Care and Treatment Programs (ICAP) supports HIV 
care and PMTCT programs in eight different African countries.  Figure 26, shows the general 
trend across all the African sites supported through ICAP over a two year period from 2007 
to 2009.  It is encouraging to see that there has been a general trend away from sd-NVP to 
multi-drug regimens, primarily AZT+sd-NVP (ICAP 2010).  With more comprehensive 
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treatment coverage, and more effective PMTCT including combination therapy with AZT in 
addition to sd-NVP, futher significant reductions in child mortality is expected.  
Although, progress is being made on the problem of pediatric HIV.  The ultimate 
solution lies in the prevention of mother-to-child transmission and in preventing HIV 
infection in women.  In order for lower resource countries to achieve clinical and 
immunological outcomes comparable to those seen in higher resource countries such as the 
United States, the scaling-up of HIV treatment and PMTCT programs needs to be realized.  
 
ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION IS POSSIBLE  
  Recently in 2009, UNAIDS and partners have called for virtual elimination of HIV 
transmission from mother-to-child by 2015.  Virtual elimination includes the overarching 
goal of keeping mothers alive, reducing the number of new child HIV infections by 90% 
between 2009 and 2015, and reducing MTCT to less than 5%.  To achieve this, the United 
Nations recommends the use of their previously mentioned four-pronged approach: (1) 
primary prevention of HIV infection of women of childbearing age (2) preventing 
unintended pregnancies among HIV+ women (3) preventing MTCT (4) provided treatment 
to HIV+ mothers and their families (UNAIDS 2010).  In 2009, there were 347,000 new child 
infections. A 90% reduction would require fewer than 34,700 new infections in 2015 (Mahy 
et al. 2010).  This is an ambitious aim, but also a realistic one that can be achieved with 
significantly increased implementation of proven strategies. Many lower income countries 
have already moved significantly towards achieving these goals by achieving at least 80% 
coverage of services to prevent MTCT, with global coverage reaching 53% (UNAIDS 2010).   
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 Projecting into the future, if current programs were improved so that by 2015 90% 
of HIV+ pregnant women were provided with ART or effective ARV prophylaxis during 
pregnancy and throughout breastfeeding as currently recommended by WHO, 
approximately 1,041,000 new child infections would be averted (Figure 27).   This is a 60% 
reduction in the annual number of new child infections, which is a major step forward but 
still well below the goal of 90% (Mahy et al. 2010).   
 
 
Figure 27.  New HIV infections in children ages 0-14 through MTCT for different scenarios 2009-2015 
(Mahy et al. 2010). 
 
 Even if there is not exactly a 90% reduction of new child HIV infections by 2015, it is 
important to note that it is still feasible to one day stop MTCT of HIV.  If HIV+ pregnant 
women and their children have  timely access to quality ARVs—for their own health or as 
prophylaxis to stop HIV transmission during pregnancy, delivery, and breastfeeding—it is 
possible to stop new HIV infections among children and keep their mothers alive.  This is 
where the importance of moving rapidly to the new, more effective ARV interventions 
recommended in the 2010 WHO guidelines comes into play.  Using the new WHO guidelines 
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for ARVs, MTCT can be virtually eliminated and together with a comprehensive approach to 
reduce new infections in women and meet family planning needs, rapid progress can be 
made towards virtual elimination.  
 
CONCLUSIONS 
 Ultimately, a large number of mothers and children continue to receive sub-optimal 
single-dose nevirapine as their main HIV prophylaxis.  This must be phased out not only in 
accordance with the 2010 WHO guidelines, but in order to reach the new target of virtual 
elimination of mother-to-child transmission. 
It is clear that the use of sd-NVP places both mother and child at risk for acquiring 
NNRTI resistance mutations which creates challenges to achieving successful subsequent 
treatment.  NNRTI resistance in infants exposed to sd-NVP compromises the response to 
subsequent NNRTI-based treatment and can jeopardize simpler first-line treatment, 
necessitating the use of second-line regimens containing drugs that are costlier and more 
difficult to administer.  This is particularly worrisome in infants initiating lifelong therapy.  
  LPV/r-based ART is the preferred regimen for HIV-infected infants with prior NVP 
exposure for PMTCT prophylaxis.  However, there are multiple issues associated with LPV/r 
and there are few options currently available for children who do not tolerate or fail first-
line LPV/r-based ART. 
 On the other hand, a program to prevent MTCT that cannot deliver or ensure 
adherence to a more complex prophylaxis regimen is less effective than a program that 
implements the simpler sd-NVP regimen even though the more complex regimen may have 
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shown greater efficacy in clinical trials.  Although sd-NVP may not be the most optimal 
regimen, it is important to realize that there are still more than a thousand new pediatric 
infections occurring each day, primarily due to mother-to-child transmission.  Sd-NVP will 
always outweigh the high risk for death and disease progression associated with no 
interventions.  
In the end, alternative approaches and new ARVs are urgently needed to ensure safe 
and successful lifelong ART for infants and children with HIV infection.  For it is the scale-up 
of more effective ARV interventions, together with a comprehensive approach to reduce 
new infections in pregnant women and meet family planning needs, that creates rapid 
progress towards virtual elimination of mother-to-child transmission of HIV.  
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